Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00686075
Registration number
NCT00686075
Ethics application status
Date submitted
23/05/2008
Date registered
29/05/2008
Date last updated
26/09/2014
Titles & IDs
Public title
A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants
Query!
Scientific title
A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-old Children and in 2 Month-old Infants
Query!
Secondary ID [1]
0
0
MI-CP178
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Healthy
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - MEDI-534, Cohort 1
Other interventions - Placebo, Cohort 1
Other interventions - MEDI-534, Cohort 2
Other interventions - Placebo, Cohort 2
Other interventions - MEDI-534, Cohort 3
Other interventions - Placebo, Cohort 3
Other interventions - MEDI-534, Cohort 4
Other interventions - Placebo, Cohort 4
Other interventions - MEDI-534, Cohort 5
Other interventions - Placebo, Cohort 5
Experimental: MEDI-534, Cohort 1 - Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
Placebo Comparator: Placebo, Cohort 1 - Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
Experimental: MEDI-534, Cohort 2 - Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo Comparator: Placebo, Cohort 2 - Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
Experimental: MEDI-534, Cohort 3 - Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo Comparator: Placebo, Cohort 3 - Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
Experimental: MEDI-534, Cohort 4 - Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo Comparator: Placebo, Cohort 4 - Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
Experimental: MEDI-534, Cohort 5 - Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo Comparator: Placebo, Cohort 5 - Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
Other interventions: MEDI-534, Cohort 1
Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
Other interventions: Placebo, Cohort 1
Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
Other interventions: MEDI-534, Cohort 2
Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
Other interventions: Placebo, Cohort 2
Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
Other interventions: MEDI-534, Cohort 3
Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
Other interventions: Placebo, Cohort 3
Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
Other interventions: MEDI-534, Cohort 4
Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
Other interventions: Placebo, Cohort 4
Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
Other interventions: MEDI-534, Cohort 5
Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
Other interventions: Placebo, Cohort 5
Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Solicited Symptoms After Dose 1
Query!
Assessment method [1]
0
0
Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever greater than or equal to (>=) 100.4 degrees Fahrenheit (F), runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.
Query!
Timepoint [1]
0
0
Within 28 days after Dose 1
Query!
Primary outcome [2]
0
0
Number of Participants With Solicited Symptoms After Dose 2
Query!
Assessment method [2]
0
0
Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever >=100.4 degrees F, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.
Query!
Timepoint [2]
0
0
Within 28 days after Dose 2
Query!
Primary outcome [3]
0
0
Number of Participants With Solicited Symptoms After Dose 3
Query!
Assessment method [3]
0
0
Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever >=100.4 degrees F, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.
Query!
Timepoint [3]
0
0
Within 28 days after Dose 3
Query!
Primary outcome [4]
0
0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 1
Query!
Assessment method [4]
0
0
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAEs) for Dose 1 are events between administration of Dose 1 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 1 were reported.
Query!
Timepoint [4]
0
0
Within 28 days after Dose 1
Query!
Primary outcome [5]
0
0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 2
Query!
Assessment method [5]
0
0
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-Emergent Adverse Events (TEAEs) for Dose 2 are events between administration of Dose 2 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 2 were reported.
Query!
Timepoint [5]
0
0
Within 28 days after Dose 2
Query!
Primary outcome [6]
0
0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 3
Query!
Assessment method [6]
0
0
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-Emergent Adverse Events (TEAEs) for Dose 3 are events between administration of Dose 3 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 3 were reported.
Query!
Timepoint [6]
0
0
Within 28 days after Dose 3
Query!
Primary outcome [7]
0
0
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 1
Query!
Assessment method [7]
0
0
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 1 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 1 were reported.
Query!
Timepoint [7]
0
0
Within 28 days after Dose 1
Query!
Primary outcome [8]
0
0
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 2
Query!
Assessment method [8]
0
0
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 2 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 2 were reported.
Query!
Timepoint [8]
0
0
Within 28 days after Dose 2
Query!
Primary outcome [9]
0
0
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 3
Query!
Assessment method [9]
0
0
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 3 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 3 were reported.
Query!
Timepoint [9]
0
0
Within 28 days after Dose 3
Query!
Primary outcome [10]
0
0
Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 1
Query!
Assessment method [10]
0
0
An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.
Query!
Timepoint [10]
0
0
Within 28 days after Dose 1
Query!
Primary outcome [11]
0
0
Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 2
Query!
Assessment method [11]
0
0
An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.
Query!
Timepoint [11]
0
0
Within 28 days after Dose 2
Query!
Primary outcome [12]
0
0
Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 3
Query!
Assessment method [12]
0
0
An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.
Query!
Timepoint [12]
0
0
Within 28 days after Dose 3
Query!
Secondary outcome [1]
0
0
Number of Participants Who Shed Vaccine-Type Virus
Query!
Assessment method [1]
0
0
Nasal wash specimens were collected to assess vaccine virus recovery in the upper respiratory tract on 7, 12 and 28 days after each dosing.
Query!
Timepoint [1]
0
0
7, 12 and 28 days after Dose 1, 2 and 3
Query!
Secondary outcome [2]
0
0
Percentage of Participants With a Seroresponse to Respiratory Syncytial Virus (RSV) and Human Parainfluenza Virus Type 3 (hPIV3) After Dose 3
Query!
Assessment method [2]
0
0
Seroresponse was defined as a >=4-fold rise from Baseline in neutralizing antibody titer, regardless of Baseline serostatus. Respiratory Syncytial Virus (RSV) and hPIV3 antibody titers were determined by using microneutralization assay and hemagglutination inhibition assay, respectively. Clopper-pearson exact confidence interval was reported.
Query!
Timepoint [2]
0
0
Day 28 after Dose 3
Query!
Secondary outcome [3]
0
0
Genotypic Stability of Recovered Vaccine-Type Virus
Query!
Assessment method [3]
0
0
Nasal wash samples with vaccine-type virus were evaluated for genotypic stability, defined as the presence of the entire RSV-Fusion (RSV F) insert based on the RSV F sequence results. If the insert was absent or truncated, the recovered virus was counted as genotypically unstable. Nasal wash samples were categorized as genotypically stable, genotypically unstable or undetermined genotypic stability.
Query!
Timepoint [3]
0
0
Within 28 days after any dose
Query!
Secondary outcome [4]
0
0
Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) Through 365 Days After Randomization
Query!
Assessment method [4]
0
0
An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea. MA-LRIs occurring within 28 days post any dose and after 28 days post any dose were summarized separately.
Query!
Timepoint [4]
0
0
Day 0 to Day 365
Query!
Secondary outcome [5]
0
0
Number of Participants With Significant New Medical Conditions (SNMCs) Through 365 Days After Randomization
Query!
Assessment method [5]
0
0
An SNMC was a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. Examples of SNMCs include diabetes, asthma, autoimmune disease (for example, lupus, rheumatoid arthritis), and neurological disease (for example, epilepsy, autism).
Query!
Timepoint [5]
0
0
Day 0 to Day 365
Query!
Secondary outcome [6]
0
0
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through 365 Days After Randomization
Query!
Assessment method [6]
0
0
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events after administration of drug which were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) within 365 days after randomization were reported.
Query!
Timepoint [6]
0
0
Day 0 to Day 365
Query!
Eligibility
Key inclusion criteria
- Male or female whose age on the day of randomization falls within one of the two age
groups:
6 to less than (<) 24 months (more than [>] 6 months of age and not yet reached their
2nd year birthday), Cohorts 1 and 2 2 months (+/- 4 weeks), Cohorts 3, 4, and 5
- Cohorts 1 and 2 only: Subject is seronegative to both Respiratory Syncytial Virus
(RSV) and human Parainfluenza Virus Type 3 (hPIV3) at Screening
- Subject whose gestational age was greater than or equal to (>=) 36 weeks
- Subject is in general good health with normal growth (that is, body weight greater
than (>) third percentile per world health organization [WHO] simplified
weight-per-age field tables
- Subject's legal representative is available by telephone
- Written informed consent and Health Insurance Portability and Accountability Act
(HIPAA) authorization (if applicable) obtained from the subject's legal representative
- Subject's legal representative is able to understand and comply with the requirements
of the protocol as judged by the investigator
- Subject is available to complete the follow-up period 1-year after receipt of the
first dose of study vaccine
- Subject's legal representative must be willing and able to bring the subject to the
study site for evaluation of respiratory illness in accordance with the protocol.
Query!
Minimum age
2
Months
Query!
Query!
Maximum age
23
Months
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- Any fever (>=100.4 degrees Fahrenheit [>=38.0 degrees Celsius], regardless of route)
or lower respiratory illness within 7 days prior to randomization
- Moderate or severe nasal congestion that in the investigator's opinion could interfere
with intranasal delivery of study vaccine
- Acute illness (defined as the presence of moderate or severe signs and symptoms) at
the time of randomization
- Any drug therapy (chronic or other) within 7 days prior to randomization or expected
receipt through the protocol-specified blood collection 28 days after each study
vaccine dosing, except that infrequent use of over-the-counter medications for the
systemic treatment of common childhood symptoms (that is, pain relievers,
decongestants or cough suppressants) are permitted according to the judgment of the
investigator
- Any current or expected receipt of immunosuppressive agents including steroids (>=2
milligram per kilogram [mg/kg] per day of prednisone or its equivalent, or >=20
milligram per day [mg/day] if the subject weighs >10 kilogram [kg], given daily or on
alternate days for >=14 days); children in this category should not receive study
vaccine until immunosuppressive agents including corticosteroid therapy have been
discontinued for >=30 days; the use of topical steroids is permitted according to the
judgment of the investigator
- History of receipt of blood transfusion or expected receipt through the
protocol-specified blood collection at 28 days after final study dosing
- History of receipt of immunoglobulin products or expected receipt through the
protocol-specified blood collection at 28 days after final study dosing
- Receipt of any investigational drug within 60 days prior to randomization or expected
receipt through 180 days after final study dosing
- Receipt of any live virus vaccine (excluding oral polio vaccine and rotavirus vaccine)
within 28 days prior to randomization or expected receipt within a 28-day window
around any study vaccine dose
- Receipt of any inactivated (that is, non-live) vaccine or oral polio vaccine or
rotavirus vaccine within 14 days prior to randomization or expected receipt within a
14-day window around any study vaccine dose
- Known or suspected immunodeficiency, including human immunodeficiency virus (HIV)
infection
- Expected to be living in the same home or enrolled in the same classroom at day care
with infants <6 months within 28 days after each dose
- Living in a household with another child who is concurrently enrolled in a study of a
live viral vaccine (including this study)
- Expected contact with a pregnant caregiver within 28 days after each dose
- A household contact who is immunocompromised; the subject should also avoid close
contact with immunocompromised individuals for at least 28 days after any study
vaccine dose
- Expected household contact within 28 days after each dose with a health care provider
for immunocompromised subjects or who is a day care provider for infants under the age
of 6 months
- History of allergic reaction to any component of the study vaccine
- Previous medical history, or evidence, of an intercurrent or chronic illness that, in
the opinion of the investigator, may compromise the safety of the subject
- Known or suspected active or chronic hepatitis infection
- History of medical diagnosis of asthma, reactive airway disease, wheezing requiring
medication, cystic fibrosis, bronchopulmonary dysplasia, chronic pulmonary disease,
medically confirmed apnea, hospitalization for respiratory illness or mechanical
ventilation for respiratory illness (excludes elective mechanical ventilation during
surgery for subjects in Cohorts 1 and 2)
- Family member or household contact who is an employee of the research center or
otherwise involved with the conduct of the study
- Any condition that, in the opinion of the investigator, might interfere with study
vaccine evaluation.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1338
Query!
Recruitment in Australia
Recruitment state(s)
ACT,QLD,SA,WA
Query!
Recruitment hospital [1]
0
0
Research Site - Garran
Query!
Recruitment hospital [2]
0
0
Research Site - Herston
Query!
Recruitment hospital [3]
0
0
Research Site - North Adelaide
Query!
Recruitment hospital [4]
0
0
Research Site - Subiaco
Query!
Recruitment postcode(s) [1]
0
0
2605 - Garran
Query!
Recruitment postcode(s) [2]
0
0
4006 - Herston
Query!
Recruitment postcode(s) [3]
0
0
5006 - North Adelaide
Query!
Recruitment postcode(s) [4]
0
0
6008 - Subiaco
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Nebraska
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nevada
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
North Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Ohio
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Oregon
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Pennsylvania
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Tennessee
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Utah
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Virginia
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
West Virginia
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Rio Grande do Sul
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
SP
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Porto alegre - RS
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Porto Alegre/RS
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Ribeirao Preto - SP
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Sao Paulo - SP
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
São Paulo
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Ontario
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Saskatchewan
Query!
Country [34]
0
0
Finland
Query!
State/province [34]
0
0
Helsinki
Query!
Country [35]
0
0
Finland
Query!
State/province [35]
0
0
Jarvenpaa
Query!
Country [36]
0
0
Finland
Query!
State/province [36]
0
0
Kokkola
Query!
Country [37]
0
0
Finland
Query!
State/province [37]
0
0
Kuopio
Query!
Country [38]
0
0
Finland
Query!
State/province [38]
0
0
Lahti
Query!
Country [39]
0
0
Finland
Query!
State/province [39]
0
0
Oulu
Query!
Country [40]
0
0
Finland
Query!
State/province [40]
0
0
Pori
Query!
Country [41]
0
0
Finland
Query!
State/province [41]
0
0
Tampere
Query!
Country [42]
0
0
Finland
Query!
State/province [42]
0
0
Turku
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Berlin
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Freiburg
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Mainz
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Netanya
Query!
Country [47]
0
0
South Africa
Query!
State/province [47]
0
0
Gauteng
Query!
Country [48]
0
0
South Africa
Query!
State/province [48]
0
0
Western Cape
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
Andalucia
Query!
Country [50]
0
0
Spain
Query!
State/province [50]
0
0
Andalucía
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
Cataluna
Query!
Country [52]
0
0
Spain
Query!
State/province [52]
0
0
Comunidad Valenciana
Query!
Country [53]
0
0
Spain
Query!
State/province [53]
0
0
Galicia
Query!
Country [54]
0
0
Spain
Query!
State/province [54]
0
0
Madrid, Communidad de
Query!
Country [55]
0
0
Spain
Query!
State/province [55]
0
0
Pais Vasco
Query!
Country [56]
0
0
Spain
Query!
State/province [56]
0
0
Esplugues de Llobregat
Query!
Country [57]
0
0
Spain
Query!
State/province [57]
0
0
Madrid
Query!
Country [58]
0
0
Spain
Query!
State/province [58]
0
0
Málaga
Query!
Country [59]
0
0
Spain
Query!
State/province [59]
0
0
Valencia
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
MedImmune LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Primary objective of this study is to describe the safety and tolerability of multiple doses
of MEDI-534 in children 6 to less than (<) 24 months of age and in infants 2 months of age.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00686075
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Elissa Malkin, D.O.
Query!
Address
0
0
MedImmune LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00686075
Download to PDF